CN101578086A - 化妆品组合物 - Google Patents
化妆品组合物 Download PDFInfo
- Publication number
- CN101578086A CN101578086A CNA200880001821XA CN200880001821A CN101578086A CN 101578086 A CN101578086 A CN 101578086A CN A200880001821X A CNA200880001821X A CN A200880001821XA CN 200880001821 A CN200880001821 A CN 200880001821A CN 101578086 A CN101578086 A CN 101578086A
- Authority
- CN
- China
- Prior art keywords
- compositions
- water
- skin
- present
- sec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 154
- 239000002537 cosmetic Substances 0.000 title claims abstract description 21
- 239000004094 surface-active agent Substances 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 17
- -1 Hydroxy fatty acid Chemical class 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 28
- 239000012071 phase Substances 0.000 claims description 26
- 239000003153 chemical reaction reagent Substances 0.000 claims description 25
- 229920006395 saturated elastomer Polymers 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000000194 fatty acid Substances 0.000 claims description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 12
- 229930195729 fatty acid Natural products 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 11
- 230000002087 whitening effect Effects 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 230000000475 sunscreen effect Effects 0.000 claims description 8
- 239000000516 sunscreening agent Substances 0.000 claims description 8
- 229930003270 Vitamin B Natural products 0.000 claims description 7
- 235000019156 vitamin B Nutrition 0.000 claims description 7
- 239000011720 vitamin B Substances 0.000 claims description 7
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 230000003750 conditioning effect Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002280 amphoteric surfactant Substances 0.000 claims description 4
- 239000003945 anionic surfactant Substances 0.000 claims description 4
- 239000003093 cationic surfactant Substances 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 description 56
- 239000000047 product Substances 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 230000009286 beneficial effect Effects 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 241001597008 Nomeidae Species 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 230000035807 sensation Effects 0.000 description 9
- 230000007613 environmental effect Effects 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 239000007859 condensation product Substances 0.000 description 6
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 6
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 244000060011 Cocos nucifera Species 0.000 description 5
- 235000013162 Cocos nucifera Nutrition 0.000 description 5
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000004906 toe nail Anatomy 0.000 description 5
- CRDAMVZIKSXKFV-YFVJMOTDSA-N (2-trans,6-trans)-farnesol Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO CRDAMVZIKSXKFV-YFVJMOTDSA-N 0.000 description 4
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 229940043259 farnesol Drugs 0.000 description 4
- 229930002886 farnesol Natural products 0.000 description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 229920000151 polyglycol Polymers 0.000 description 4
- 239000010695 polyglycol Substances 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 description 4
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 229960000735 docosanol Drugs 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000002337 glycosamines Chemical class 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 3
- 239000002563 ionic surfactant Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 description 3
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 description 3
- 235000002378 plant sterols Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000001294 propane Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000037075 skin appearance Effects 0.000 description 3
- 239000001587 sorbitan monostearate Substances 0.000 description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 description 3
- 229940035048 sorbitan monostearate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- RTBWWWVNZWFNBV-SFHVURJKSA-N (2s)-3-phenyl-2-(undec-10-enoylamino)propanoic acid Chemical compound C=CCCCCCCCCC(=O)N[C@H](C(=O)O)CC1=CC=CC=C1 RTBWWWVNZWFNBV-SFHVURJKSA-N 0.000 description 2
- WUOACPNHFRMFPN-VIFPVBQESA-N (R)-(+)-alpha-terpineol Chemical compound CC1=CC[C@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-VIFPVBQESA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 description 2
- IQGWPPQNIZBTBM-UHFFFAOYSA-N 2-aminoethanol;sulfuric acid Chemical compound NCCO.OS(O)(=O)=O IQGWPPQNIZBTBM-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 235000002673 Dioscorea communis Nutrition 0.000 description 2
- 241000544230 Dioscorea communis Species 0.000 description 2
- 239000005792 Geraniol Substances 0.000 description 2
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- 208000035753 Periorbital contusion Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229910010413 TiO 2 Inorganic materials 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229940113087 geraniol Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 description 2
- 235000011151 potassium sulphates Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- CZKPBCHPLNOUSJ-UHFFFAOYSA-N 1-octadecoxyperoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOOOCCCCCCCCCCCCCCCCCC CZKPBCHPLNOUSJ-UHFFFAOYSA-N 0.000 description 1
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- UOFCAQWHTQFNHS-UHFFFAOYSA-N 2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCO UOFCAQWHTQFNHS-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- RZRILSWMGXWSJY-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;sulfuric acid Chemical compound OS(O)(=O)=O.OCCN(CCO)CCO RZRILSWMGXWSJY-UHFFFAOYSA-N 0.000 description 1
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- LIFHMKCDDVTICL-UHFFFAOYSA-N 6-(chloromethyl)phenanthridine Chemical compound C1=CC=C2C(CCl)=NC3=CC=CC=C3C2=C1 LIFHMKCDDVTICL-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 206010004950 Birth mark Diseases 0.000 description 1
- FYZWDBYXDUGMTD-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCC(=O)[Na] Chemical compound CCCCCCCCCCCCCCCCCCC(=O)[Na] FYZWDBYXDUGMTD-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- PMJRJYZRNYNQDP-UHFFFAOYSA-N N(=O)OC(C)CCCCCC.COC1=CC=C(C=CC(=O)O)C=C1 Chemical compound N(=O)OC(C)CCCCCC.COC1=CC=C(C=CC(=O)O)C=C1 PMJRJYZRNYNQDP-UHFFFAOYSA-N 0.000 description 1
- BFWXAYQEKYNZQU-UHFFFAOYSA-N N(=O)OC(C)CCCCCC.OC1=C(C(=O)O)C=CC=C1 Chemical compound N(=O)OC(C)CCCCCC.OC1=C(C(=O)O)C=CC=C1 BFWXAYQEKYNZQU-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- PHIIYDSPMYGDAF-UHFFFAOYSA-N S(=O)(=O)(O)O.C(CCCCCCCCCCC)[K] Chemical compound S(=O)(=O)(O)O.C(CCCCCCCCCCC)[K] PHIIYDSPMYGDAF-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- YGUMNXUBAJCWHV-UHFFFAOYSA-L [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCC(=O)OCC(O)CO Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCC(=O)OCC(O)CO YGUMNXUBAJCWHV-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229940071097 ascorbyl phosphate Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- MKHVZQXYWACUQC-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;dodecyl sulfate Chemical compound OCCNCCO.CCCCCCCCCCCCOS(O)(=O)=O MKHVZQXYWACUQC-UHFFFAOYSA-N 0.000 description 1
- PMIUHGKUXIEDLL-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;hydrogen sulfate Chemical compound OS(O)(=O)=O.OCCNCCO PMIUHGKUXIEDLL-UHFFFAOYSA-N 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- QVBODZPPYSSMEL-UHFFFAOYSA-N dodecyl sulfate;2-hydroxyethylazanium Chemical compound NCCO.CCCCCCCCCCCCOS(O)(=O)=O QVBODZPPYSSMEL-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- 229960000655 ensulizole Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- GFMIDCCZJUXASS-UHFFFAOYSA-N hexane-1,1,6-triol Chemical compound OCCCCCC(O)O GFMIDCCZJUXASS-UHFFFAOYSA-N 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- JNONJXMVMJSMTC-UHFFFAOYSA-N hydron;triethylazanium;sulfate Chemical compound OS(O)(=O)=O.CCN(CC)CC JNONJXMVMJSMTC-UHFFFAOYSA-N 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 description 1
- XSEOYPMPHHCUBN-FGYWBSQSSA-N hydroxylated lecithin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCC[C@@H](O)[C@H](O)CCCCCCCC XSEOYPMPHHCUBN-FGYWBSQSSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 1
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- KKXWPVVBVWBKBL-UHFFFAOYSA-N n,n-diethylethanamine;dodecyl hydrogen sulfate Chemical compound CC[NH+](CC)CC.CCCCCCCCCCCCOS([O-])(=O)=O KKXWPVVBVWBKBL-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-UHFFFAOYSA-N octinoxate Chemical compound CCCCC(CC)COC(=O)C=CC1=CC=C(OC)C=C1 YBGZDTIWKVFICR-UHFFFAOYSA-N 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- FJCFFCXMEXZEIM-UHFFFAOYSA-N oxiniacic acid Chemical compound OC(=O)C1=CC=C[N+]([O-])=C1 FJCFFCXMEXZEIM-UHFFFAOYSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002948 pantothenic acids Chemical class 0.000 description 1
- 229940072880 peg-10 stearate Drugs 0.000 description 1
- 229940077414 peg-12 stearate Drugs 0.000 description 1
- 229940119517 peg-6 stearate Drugs 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940078491 ppg-15 stearyl ether Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 125000002678 retinoid group Chemical group 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940045998 sodium isethionate Drugs 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- PBDAWQLIMPWEEF-JEDNCBNOSA-M sodium;(2s)-2,6-diaminohexanoate Chemical compound [Na+].NCCCC[C@H](N)C([O-])=O PBDAWQLIMPWEEF-JEDNCBNOSA-M 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- LADXKQRVAFSPTR-UHFFFAOYSA-M sodium;2-hydroxyethanesulfonate Chemical compound [Na+].OCCS([O-])(=O)=O LADXKQRVAFSPTR-UHFFFAOYSA-M 0.000 description 1
- DUXXGJTXFHUORE-UHFFFAOYSA-M sodium;4-tridecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1 DUXXGJTXFHUORE-UHFFFAOYSA-M 0.000 description 1
- MZSDGDXXBZSFTG-UHFFFAOYSA-M sodium;benzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=CC=C1 MZSDGDXXBZSFTG-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- PBSRSWFGYPZDAU-FFIPNUABSA-H trimagnesium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-oxido-5-oxo-2h-furan-4-yl] phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] PBSRSWFGYPZDAU-FFIPNUABSA-H 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0295—Liquid crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及一种组合物,所述组合物包含约0.1%至约10%的疏水性结构化试剂;约0.1%至约10%的亲水性表面活性剂;约0.01%至约5%的非交联的水溶性聚合物;以及水,其中所述组合物具有高于约15,000cps的粘度,并且在约0.1rad/sec至约1rad/sec的角频率范围内具有低于约15,000dyne/cm2的最高G’和高于约0.4的最高tanδ。本发明还涉及美容产品,所述产品包含a)组合物,所述组合物包含约0.1%至约10%的疏水性结构化试剂;约0.1%至约10%的亲水性表面活性剂;约0.01%至约5%的非交联的水溶性聚合物和水,和b)包含所述组合物的容器,其中所述组合物具有高于15,000cps的粘度,并且当其表面被扭曲以具有高于约150的Sa时,在约24小时内恢复其表面平整度至具有低于约80的Sa。
Description
发明领域
本发明涉及化妆品组合物、美容产品和它们的制备方法,它们提供消费者可接受的美观,具体地讲新的使用体验。
发明背景
消费者可获得多种产品以提供护肤有益效果。为了达到最佳效果,有些产品必须有规律地和长期地施用。虽然具体的护肤活性物质或化合物(其可帮助调理皮肤和/或减轻由多种外在和内在因素造成的损伤)的递送当然重要,但是为了鼓励经常使用,产品在施用前或之后均具有令人愉快的外观和感觉也是重要的。例如,提供全新表面外观的产品在使用期间可以由产品外观向消费者递送清新的感觉。
那些期望更多有益效果和/或保护作用的消费者趋于选择较粘稠的产品。例如,霜膏或凝胶组合物趋于被认为可提供比护肤液更好的皮肤有益效果。霜膏或凝胶一般具有高于15,000cps的粘度,并且显示出类似固体的流变学性能。当广口瓶内的霜膏或凝胶型产品被首次打开时,其具有很好成型的美学上吸引人的平滑外观。然而,就在首次使用之后,和此后的每次使用时,消费者将她的手指蘸入广口瓶中,产品的表面留下沟和凹陷。
基于前文所述,需要提供具有足以传达增加的有益效果的稠度的化妆品组合物,该化妆品组合物提供平坦和光亮的产品外观以递送清新和令人愉快的感觉。
没有任何现有技术能提供本发明的全部优点和有益效果。
发明概述
本发明涉及一种化妆品组合物,所述组合物包含:约0.1%至约10%的疏水性结构化试剂;约0.1%至约10%的亲水性表面活性剂;约0.01%至约5%的非交联的水溶性聚合物;以及水,其中所述组合物具有高于约15,000cps的粘度,并且在约0.1rad/sec至约1rad/sec的角频率范围内具有低于约15,000dyne/cm2的最高G’和高于约0.4的最高tanδ。
本发明还涉及一种美容产品,所述组产品包含:a)包含约0.1%至约10%的疏水性结构化试剂;约0.1%至约10%的亲水性表面活性剂;约0.01%至约5%的非交联的水溶性聚合物;以及水的组合物,和b)包含所述组合物的容器,其中所述组合物具有高于约15,000cps的粘度,并且在约0.1rad/sec至约1rad/sec的角频率范围内具有低于约15,000dyne/cm2的最高G’和高于约0.4的最高tanδ。
本发明还涉及一种美容产品,所述组产品包含:a)包含约0.1%至约10%的疏水性结构化试剂;约0.1%至约10%的亲水性表面活性剂;约0.01%至约5%的非交联的水溶性聚合物;以及水的组合物,和b)包含所述组合物的容器,其中所述组合物具有高于15,000cps的粘度,并且当其表面被扭曲至具有高于约150的Sa时,在约24小时之内恢复其表面平整度至具有低于80的Sa。
本发明还涉及制备本发明的组合物的方法,所述方法包括:a)通过混合疏水性结构化试剂和亲水性表面活性剂以及用于油相的任选成分来制备油相,b)通过混合水溶性树胶型聚合物、水和用于油相的任选成分来制备含水相,和c)将油相分散到含水相中。
本发明还涉及使用此类组合物以调节皮肤状况的方法,所述方法包括涂敷到需要处理的人的皮肤上。
对于本领域的技术人员来说,通过阅读本说明书的公开内容,本发明的这些和其它特征、方面和优点将变得显而易见。
附图概述
虽然在说明书之后提供了特别指出和清楚地要求保护本发明的权利要求书,但是据信通过下面的描述并结合附图可以更好地理解本发明,其中:
图1A至D是本发明优选的实施方案的照片。
图2A至D是比较实施例的照片。
图3是本发明优选的实施方案和比较实施例的log摆动频率(x-轴)对tanδ(y-轴)的曲线图。
图4是本发明优选的实施方案和比较实施例的log摆动频率(x-轴)对G’(y-轴)的曲线图。
发明详述
虽然在说明书之后提供了特别指出和清楚地要求保护本发明的权利要求书,但是据信通过下面的描述可以更好地理解本发明。
除非另外指明,本文所使用的所有百分比和比率均以总组合物的重量计,并且所有的测量均在25℃进行。
如本文所用,术语“化妆品组合物”是指适于局部涂敷到哺乳动物角质组织上的那种。术语“皮肤护理产品”所涵盖的产品包括但不限于保湿剂、个人清洁产品、吸留的药物递送贴片、指/趾甲油、粉末、擦拭物、毛发调理剂、皮肤处理乳液、剃刮膏等。
如本文所用,术语“角质组织”是指作为哺乳动物(例如,人、狗、猫等)最外面保护层设置的含角蛋白层,其包括但不限于皮肤、唇缘、毛发、趾甲、指甲、表皮、蹄部等。
如本文所用,术语“护肤活性物质”或“活性物质”是指当涂敷到皮肤上时可向皮肤提供有益效果或改善的化合物。应当理解,所述护肤活性物质不仅可用于涂敷到皮肤上,而且可用于毛发、指/趾甲以及其它哺乳动物角质组织。
除非另外指明,如本文所用,术语“环境条件”是指约一个大气压、约50%相对湿度和约25℃下的环境条件。
本发明的组合物可包括、基本上由或由本发明的组分以及本文所述的其它成分组成。
如本文所用,术语“安全和有效量”是指一定量的足以显著促使积极的有益效果的化合物或组合物,优选积极的角质组织外观或感觉有益效果,或积极的毛发外观或感觉有益效果,独立地包括本文所公开的有益效果或与其联合,但该量又足够低以避免严重的副作用,即在技术人员合理判断的范围内提供合理的效险比。
如本文所用,术语“调节皮肤状况”是指例如通过提供一种有益效果改善皮肤外观和/或感觉,如更光滑的外观和/或感觉。本文中,“改善皮肤状况”是指在视觉上和/或触觉上获得皮肤外观和感觉方面可察觉的积极改变。所述有益效果可以是慢性的有益效果且可以包括以下一种或多种:减少皱纹和粗糙深纹、细纹、裂纹、肿块和粗大毛孔的出现;增厚角质组织(如构造皮肤的表皮和/或真皮和/或皮下层,以及指/趾甲和毛干的角质层(如果适用的话)以缓解皮肤、毛发或指/趾甲萎缩);增加真皮-表皮边缘的盘旋结构(还被称为网缘);防止由于例如皮肤功能性弹性蛋白的丧失、损伤和/或失活而造成皮肤或毛发弹性丧失,导致诸如弹性组织变性、松垂、丧失皮肤或毛发变形回复功能这些状况;减少脂肪团;皮肤、毛发或趾甲色调的变化,例如黑眼圈、红斑(例如由于例如红斑痤疮产生的不均匀红色调),灰黄,由色素沉着过度引起的变色等。
如本文所用,术语“G”是指弹性(储能)模量,其是当向组合物施加应变时所储存的和恢复的能量的量的量度。
如本文所用,术语“G”是指粘性(损耗)模量,其是当向组合物施加应变时作为热散失的能量的量的量度。
如本文所用,术语“tanδ”是指组合物的G”/G’的比率。
除非另外指明,所有的百分比、份数和比率均以本发明的皮肤护理组合物的总重量计。除非另外指明,所有与所列成分相关的上述重量均基于活性物质的含量,因此不包括可能包含在市售原料中的载体或副产物。
本文所引用的所有出版物均以此方式全文以引用方式并入。
本发明的组合物可用于调节皮肤状况,并且尤其可用于调节角质组织状况。
本发明的组合物还可提供附加有益效果,所述附加有益效果包括稳定性、无显著(消费者不能接受的)皮肤刺激性和良好美学特性。
本发明的组合物具有霜膏或凝胶外观,其具有高于15,000cps,优选在约20,000cps至约100,000cps范围内的粘度。
本发明的组合物在约0.1rad/sec至约1rad/sec的角频率时具有高于约0.4,优选高于约0.5的最高tanδ。在约0.1rad/sec至约1rad/sec的角频率范围内,所述组合物的Tanδ可反比于角频率。
每次通过例如消费者的手指或某些其它的手动涂敷器,从容器移除一部分本发明的组合物或者扰动或改变所述组合物的表面,容器中的组合物恢复平坦和光滑的表面,并且看起来就像首次打开容器时的那样。
不受理论的约束,本发明的组合物具有弱的凝胶网络,但是仍然具有足够高的粘度以维持霜膏或凝胶外观,并且据信该弱的凝胶网络使得所述组合物的平坦表面能够在消费者使用之后在环境条件下恢复。可明显地观察到平坦表面的恢复。平坦表面看得出的恢复可由依照测试方法中提供的表面的算术平均偏差测量而测得的表面的算术平均偏差(Sa)表征。Sa是一个标准参数,其是本领域已知的,并且被定义为样本区域内的平均平面之上和之下的表面偏离的绝对值的算术平均。本发明的组合物,当被置于容器中时,当通过例如由消费者一般使用带出一部分组合物其表面被扭曲以具有高于约150的Sa时,在环境条件下在24小时之内,优选约12小时,恢复其平坦表面至具有低于约80的Sa。更优选地,本发明的组合物当其表面被扭曲以具有高于约150的Sa时,在环境条件下,在约12小时内恢复其表面平整度至具有低于约40的Sa。
由于本发明的产品在消费者一般使用之后可恢复其平坦表面,消费者在他们每次使用产品时经历全新产品的使用体验。
本发明的组合物包含疏水性结构化试剂、表面活性剂、非交联的水溶性聚合物、和水。
本文组合物还可包括各种各样的其它成分。本发明的组合物将在下文中详细描述。
疏水性结构化试剂
本发明的组合物包含至少一种疏水性结构化试剂。疏水性结构化试剂以按重量计约0.1%至约10%,优选约0.3%至约6%,最优选约0.5%至约4%的浓度存在于本发明的组合物中。
本发明的疏水性结构化试剂选自由下列组成的组:饱和的C16至C30脂肪醇、包含约1至约5摩尔环氧乙烷的饱和的C16至C30脂肪醇、饱和的C16至C30二醇、饱和的C16至C30单甘油醚、饱和的C16至C30羟基脂肪酸、饱和的C16至C30脂肪酸、饱和的C16至C30单甘油酯、饱和的C16至C30酸单己糖醇酯以及它们的混合物,其具有至少约40℃的熔点。本发明优选的疏水性结构化试剂选自由下列组成的组:饱和的C16至C30脂肪醇、包含约1至约5摩尔环氧乙烷的饱和的C16至C30脂肪醇、饱和的C16至C30二醇、饱和的C16至C30单甘油醚、饱和的C16至C30羟基脂肪酸、饱和的C16至C30脂肪酸、饱和的C16至C30单甘油酯、饱和的C16至C30酸单己糖醇酯以及它们的混合物,其具有至少约40℃的熔点。不受理论的约束,据信这些结构化试剂对于帮助组合物流变学特性的形成是有用的,这有助于本发明组合物的水解稳定性。具体地讲,结构化试剂有助于液晶凝胶网络结构的形成。
本发明优选的结构化试剂选自由下列组成的组:硬脂醇、鲸蜡醇、二十二醇、硬脂酸、棕榈酸、平均具有约1至约5个环氧乙烷单元的硬脂醇聚乙二醇醚、平均具有约1至约5个环氧乙烷单元的鲸蜡醇聚乙二醇醚、硬脂酸的甘油酯、以及它们的混合物。本发明更优选的结构化试剂选自由下列组成的组:硬脂醇、鲸蜡醇、二十二醇、平均具有约2个环氧乙烷单元的硬脂醇聚乙二醇醚(硬脂基聚氧乙烯醚-2)、平均具有约2个环氧乙烷单元的鲸蜡醇聚乙二醇醚、硬脂酸的甘油酯、以及它们的混合物。甚至更优选的结构化试剂选自由下列组成的组:硬脂醇、鲸蜡醇、二十二醇、以及它们的混合物。
表面活性剂
本发明的组合物包含至少一种亲水性表面活性剂,其优选具有大于10的HLB。所述表面活性剂以按重量计约0.1%至约10%,优选约0.5%至约5%,最优选约1.0%至约4%的浓度存在于本发明的组合物中。
不受理论的约束,据信亲水性表面活性剂可将疏水材料如结构化试剂分散在水相中。表面活性剂的亲水性必须至少足以在水中分散。表面活性剂的正确选择将取决于所述组合物的pH和存在的其它组分。
本发明的亲水性表面活性剂可选自由下列组成的组:非离子表面活性剂、阴离子表面活性剂、阳离子表面活性剂、两性表面活性剂、以及它们的混合物。
优选可用于本文的是非离子表面活性剂。可用于本文的非离子表面活性剂中的一些,是可广义定义为长链醇如C8-30醇与糖或淀粉聚合物的缩合产物的那些,即糖苷。这些化合物可用分子式(S)·n--O--R表示,其中S是糖部分,如葡萄糖、果糖、甘露糖和半乳糖;n是约1至约1000的整数,并且R是C8-30烷基。可衍生烷基的长链醇的实例包括癸醇、鲸蜡醇、硬脂醇、月桂醇、肉豆蔻醇、油醇等。另一种有用的非离子表面活性剂包括山梨醇与脂肪酸的缩合产物。非限制性实例包括聚山梨酸酯,如得自Uniqema,USA的Tweens。另一种有用的非离子表面活性剂包括可广义定义为脂肪酸与糖如蔗糖的缩合产物的那些。糖与脂肪酸的非限制性实例包括给定的CTFA命名为蔗糖椰油酸酯的物质,其作为与脱水山梨醇硬脂酸酯的混合物以商品名Arlatone 2121售自Uniqema。其它有用的非离子表面活性剂包括烯化氧与脂肪酸的缩合产物(即,脂肪酸的烯化氧酯)。这些物质具有通式RCO(X)·n·OH,其中R是C10-30烷基,X是--OCH2CH2--(即衍生自乙二醇或环氧乙烷)或--OCH2CHCH3--(即衍生自丙二醇或环氧丙烷),并且n是约6至约100的整数。其它的非离子表面活性剂是烯化氧与2摩尔脂肪酸的缩合产物(即,脂肪酸的烯化氧二酯)。这些物质具有通式RCO(X)·n OOCR,其中R是C10-30烷基,X是--OCH2CH2--(即衍生自乙二醇或环氧乙烷)或-OCH2CHCH3--(即衍生自丙二醇或环氧丙烷),并且n是约6至约100的整数。其它非离子表面活性剂是烯化氧与脂肪醇的缩合产物(即,脂肪醇的烯化氧醚)。这些物质具有通式R(X)nOR′,其中R是C10-30烷基,X是--OCH2 CH2--(即衍生自乙二醇或环氧乙烷)或--OCH2 CHCH3--(即衍生自丙二醇或环氧丙烷),并且n是约6至约100的整数,并且R′是H或C10-30烷基。这些烯化氧衍生的非离子表面活性剂的非限制性实例包括十六烷基聚氧乙烯醚-6、十六烷基聚氧乙烯醚-10、十六烷基聚氧乙烯醚-12、鲸蜡硬脂基聚氧乙烯醚-6、鲸蜡硬脂基聚氧乙烯醚-10、鲸蜡硬脂基聚氧乙烯醚-12、硬脂基聚氧乙烯醚-6、硬脂基聚氧乙烯醚-10、硬脂基聚氧乙烯醚-12、PEG-6硬脂酸酯、PEG-10硬脂酸酯、PEG-12硬脂酸酯、PEG-20甘油基硬脂酸酯、PEG-80甘油基牛油酯、PPG-10甘油基硬脂酸酯、PEG-30甘油基椰油酸酯、PEG-80甘油基椰油酸酯、PEG-200甘油基牛油酯、PEG-8二月桂酸酯、PEG-10二硬脂酸酯、以及它们的混合物。在非离子表面活性剂中,优选的是选自由下列组成的组的那些:硬脂基聚氧乙烯醚-21、鲸蜡硬脂基聚氧乙烯醚-20、鲸蜡硬脂基聚氧乙烯醚-12、吐温-60、吐温-80、蔗糖椰油酸酯、硬脂基聚氧乙烯醚-100、PEG-100硬脂酸酯、以及它们的混合物。
本文另一种优选的表面活性剂是阴离子表面活性剂。阴离子表面活性剂的非限制性实例包括十二烷基硫酸铵、月桂基聚氧乙烯醚硫酸铵、月桂基硫酸三乙基胺、月桂基聚氧乙烯醚硫酸三乙基胺、月桂基硫酸三乙醇胺、月桂基聚氧乙烯醚硫酸三乙醇胺、月桂基硫酸单乙醇胺、月桂基聚氧乙烯醚硫酸单乙醇胺、月桂基硫酸二乙醇胺、月桂基聚氧乙烯醚硫酸二乙醇胺、月桂酸甘油单酯硫酸钠、月桂基硫酸钠、月桂基聚氧乙烯醚硫酸钠、月桂基硫酸钾、月桂基聚氧乙烯醚硫酸钾、月桂基肌氨酸钠、月桂酰肌氨酸钠、月桂酰肌氨酸、椰油基肌氨酸、椰油基硫酸铵、椰油基硫酸钠、椰油基硫酸钾、椰油基硫酸一乙醇胺、十三烷基苯磺酸钠、十二烷基基苯磺酸钠、椰油基羟乙基磺酸钠、以及它们的组合。
本文另一种优选的表面活性剂是阳离子表面活性剂。阳离子表面活性剂的非限制性实例包括季铵盐或酰氨基胺(具有至少一个包含至少约8个碳原子的脂肪链)以及它们的混合物。
本文另一种优选的表面活性剂是两性表面活性剂。两性表面活性剂的非限制性实例包括磷脂酰胆碱、氢化的磷脂酰胆碱、卵磷脂、氢化的卵磷脂、羟基化的卵磷脂、溶血卵磷脂、以及它们的混合物。
非交联的水溶性聚合物
本发明的组合物包含非交联的水溶性聚合物。非交联的水溶性聚合物以按重量计约0.01%至约5%,优选约0.1%至约0.3%,最优选约0.2%至约2%的浓度存在于本发明的组合物中。
不受理论的约束,非交联的水溶性聚合物可降低组合物的粘度并且削弱组合物的凝胶网络,其可有助于本发明的组合物的平坦表面的恢复性能。
可用于本文的非限制性类的非交联的水溶性聚合物是树胶型聚合物。可用于本文的树胶型聚合物的非限制性实例包括瓜耳胶羟丙基瓜耳、刺槐豆胶,结冷胶、纳托胶、黄原胶、以及它们的混合物。
可用于本文的另一非限制性类的非交联的水溶性聚合物是多糖聚合物。可用于本文的多糖聚合物的非限制性实例包括选自纤维素和纤维素衍生物的那些,如羧甲基纤维素、羟乙基纤维素、羟乙基乙基纤维素、甲基羟基乙基纤维素、羟丙基纤维素、羟基丙基甲基纤维素、烷基羟烷基纤维素醚、以及它们的混合物。在烷基羟烷基纤维素醚中,优选的是给定的CTFA命名为鲸蜡基羟乙基纤维素的物质,其是鲸蜡醇和羟乙基纤维素的醚,以商品名CS PLUS售自Aqualon Corporation(Wilmington,DE)。其它有用的多糖包括透明质酸钠,和小核菌葡聚糖,其为一条(1-3)连接的葡萄糖单元的直链,每三个单元具有一个(1-6)连接的葡萄糖,其可商购获得的实例是购自Michel Mercier ProductsInc.(Mountainside,NJ)的ClearogelTM CS11。
水
本发明的组合物包含水。水以约50%至约95%,优选约65%至约90%的浓度存在于本发明的组合物中。
任选成分
护肤活性物质
本发明的组合物可包括至少一种护肤活性物质。不受理论的约束,据信本发明的组合物提供在配制多种活性物质中的灵活性。
然而,在本发明的任一实施方案中,可用于本发明的活性物质可通过其所提供的有益效果或其所假定的作用方式来分类。然而应当理解,在某些情况下,可用于本发明的活性物质可提供一种以上的有益效果或通过一种以上的作用方式起作用。因此,本文中的分类仅是为了方便起见,并非旨在将活性物质限定在特定应用或所列出的应用中。
维生素B
3
化合物
维生素B3化合物(如烟酰胺)为优选可用于本文的护肤活性物质。本发明优选包含约0.1%至约30%,更优选约1%至约20%,甚至更优选约2%至约10%的维生素B3化合物。
如本文所用,“维生素B3化合物”是指具有以下分子式的化合物:
其中R是-CONH2(即烟酰胺)、-COOH(即烟酸)或-CH2OH(即烟基醇);它们的衍生物;任何上述物质的盐。前述维生素B3化合物的示例性衍生物包括烟酸酯,包括烟酸的非血管舒张性酯(例如,烟酸生育酚酯)、烟基氨基酸、烟基醇羧酸酯、烟酸N-氧化物和烟酰胺N-氧化物。
美白剂
本发明组合物可包含美白剂。可用于本文的美白剂是指与处理前相比不仅改变皮肤外观而且还改善色素沉着过度的活性成分。可用于本文的有用的美白剂包括抗坏血酸化合物、维生素B3化合物、壬二酸、丁基羟基苯甲醚、没食子酸及其衍生物、对苯二酚、曲酸、熊果苷、桑树提取物、十一碳烯酰苯基丙氨酸、氯化十六烷基吡啶鎓、甘草酸、四氢姜黄素、以及它们的混合物。还据信使用美白剂的组合是有利的,因为它们可以通过不同机理提供美白有益效果。
当使用时,所述组合物优选包含按所述组合物的重量计约0.1%至约10%,更优选约0.2%至约5%的美白剂。
抗坏血酸化合物是有用的美白剂。优选地,可用于本文的抗坏血酸化合物是抗坏血酸盐、脂肪酸的抗坏血酸基酯,以及抗坏血酸衍生物,例如抗坏血酸基磷酸酯如抗坏血酸磷酸酯镁和抗坏血酸磷酯钠、抗坏血酸基山梨酸酯、以及抗坏血酸基葡糖苷。
苯基丙氨酸十一碳烯酸酰胺是取代的氨基酸,其也可作为美白剂适用于本发明。其可以商品名Sepiwhite Msh从Seppic获得。
氯化十六烷基吡啶鎓和四氢姜黄素也适合作为美白剂用于本文。
甘草酸和甘草次酸,衍生自光果甘草的天然物质及其衍生物如甘草次酸,也适用于本文。这些物质得自Maurzen或Ichimaru Pharcos。
肽
肽可以安全和有效量包含于本发明的组合物中,所述肽包括但不限于,二肽、三肽、四肽和五肽、以及它们的衍生物。本文所用的“肽”既指天然存在的肽又指合成的肽。还可用于本发明的是天然存在的和市售的含肽组合物。
如果包含于本发明的组合物中,肽优选被包含的量按所述组合物的重量计为约1x10-6%至约10%,更优选约1x10-6%至约0.1%,甚至更优选约1x10-5%至约0.01%。
糖胺
本发明的组合物可包含安全和有效量的糖胺,其也被称为氨基糖。如本文所用,“糖胺”是指六碳糖的胺衍生物。
可用于本文的糖胺的实例包括葡糖胺、N-乙酰基葡糖胺、甘露糖胺、N-乙酰基甘露糖胺、半乳糖胺、N-乙酰基半乳糖胺。优选可用于本文的是葡糖胺。另外,可使用两种或多种糖胺的组合。
当被包括在本发明的组合物中时,糖胺的优选存在量为按所述组合物的重量计约0.001%至约20%,更优选约1%至约10%,甚至更优选约2%至约5%的糖胺。
油溶性化合物
本发明的组合物还可任选包含油溶性化合物。所述油溶性化合物可选自油溶性维生素化合物、油溶性萜烯醇、植物甾醇、以及它们的衍生物。
油溶性化合物的量按所述组合物的重量计可在约0.01%至约10%,优选约0.05%至约5%,更优选约0.1%至约3%的范围内。
本领域那些技术人员已知的许多可提供各种皮肤有益效果的维生素是油溶性的,并且它们的一些或所有衍生物均是油溶性的。此类油溶性维生素化合物的非限制性实例包括类视色素、维生素C(例如,抗坏血酸棕榈酸酯)、维生素D、维生素K、维生素E、以及它们的混合物。优选可用于本文的是类视色素、维生素E、以及它们的混合物。
可用于本文的油溶性萜烯醇包括金合欢醇、金合欢醇的衍生物、金合欢醇的异构体、香叶醇、香叶醇的衍生物、香叶醇异构体、植烷三醇、植烷三醇的衍生物、植烷三醇的异构体、以及它们的混合物。优选可用于本文的是金合欢醇。
植物甾醇及其衍生物因可提供亮肤有益效果而闻名。油溶性植物甾醇衍生物的非限制性实例包括β-谷甾醇、菜油甾醇、芸苔甾醇、羽扇豆醇、α-菠菜甾醇、豆甾醇、它们的衍生物、以及它们的组合。
皮肤调理剂
本发明的组合物还可任选包含皮肤调理剂。这些试剂可选自湿润剂、剥脱剂或润肤剂。皮肤调理剂的量按所述组合物的重量计可在约1%至约60%,优选约2%至约50%,更优选约5%至约40%的范围内。
湿润剂是多元醇,其旨在保湿、减少剥落和促进皮肤深处的剥落物脱落。典型的多元醇包括聚亚烷基二醇,并且更优选亚烷基多羟基化合物、以及它们的衍生物。例证性的为丙二醇、双丙二醇、聚丙二醇、聚乙二醇、山梨醇、羟丙基山梨醇、己二醇、1,3-丁二醇、1,2,6-己三醇、乙氧基化的甘油、丙氧基化的甘油、以及它们的混合物。最优选地,所述湿润剂是甘油。
依照本发明的剥脱剂可选自C2-C30α-羟基羧酸、β-羟基羧酸以及这些酸的盐。最优选的是乙醇酸、乳酸和水杨酸,以及它们的铵盐。
当所述调理剂是润肤剂时,其选自烃、脂肪酸、脂肪醇和酯。
防晒剂
本主题发明的组合物可任选包含防晒剂。合适的防晒剂可以是有机的或无机的。
可用于本文的无机防晒剂包括以下金属氧化物:二氧化钛、氧化锌、氧化锆、氧化铁、以及它们的混合物。
可用于本文的有机剂包括胡莫柳酯、氰双苯丙烯酸辛酯、对甲氧基肉桂酸2-乙基己酯(可作为PARSOL MCX商购获得)、苯基苯并咪唑磺酸、2-羟基-4-甲氧基二苯酮(二苯甲酮-3)、水杨酸2-乙基己酯、以及它们的混合物。
当被包含在本发明的组合物中时,防晒剂的优选含量按所述组合物的重量计为约0.1%至约20%,优选约0.5%至约10%,更优选约1%至约5%。确切的量将根据防晒剂或所选择的防晒剂和所需的防晒因子(SPF)而改变。
其它任选成分
可以将多种附加的成分掺入到本发明组合物中。这些附加成分的非限制性实例包括:改善皮肤感觉或外观的具体物质;抗痤疮活性物质;油溶性β-羟基酸如水杨酸及其衍生物;螯合剂;类黄酮化合物;抗炎剂;抗蜂窝炎剂;脱屑活性物质;抗氧化剂/自由基清除剂;美黑活性物质;皮肤抚慰或皮肤愈合活性物质如泛酸衍生物(包括泛醇、右旋泛醇、乙基泛醇)、芦荟、尿囊素、红没药醇和甘草酸二钾盐;抗微生物的或抗真菌活性物质。
组合物的制备
本发明的组合物一般通过美容产品的常规制备法来制备。上述方法通常涉及在一个或多个步骤中将成分混合至比较均一的状态,可使用或不使用加热、冷却、应用真空等。
在一个实施方案中,本发明的方法包括:
通过混合疏水性结构化试剂和表面活性剂以及用于油相的任选成分来制备油相;
通过混合水溶性树胶型聚合物、水和用于油相的任选成分来制备含水相;和
将油相分散到含水相中。
在另一个实施方案中,本发明的方法包括:
通过混合疏水性结构化试剂和表面活性剂以及用于油相的任选成分来制备油相;
通过混合水溶性树胶型聚合物、水和用于油相的任选成分来制备含水相;
通过混合皮肤活性物质、水和用于含皮肤活性物质相的任选成分制备含皮肤活性物质相;
将油相分散到含水相中;和
将含皮肤活性物质相分散到油相和含水相的混合物中。
本发明的局部用组合物可配制成面部皮肤化妆品、眼部化妆品、唇部化妆品、保湿剂、皱纹舒缓精华液、护肤液、皮肤面膜、皮肤霜膏、皮肤凝胶、眼凝胶、眼霜、唇凝胶、唇霜、化妆品、粉底、或任何其它通常已知的皮肤产品或护肤品。
局部用产品
在一个优选的实施方案中,本发明的产品是水包油乳液组合物(具有的粘度在约20,000至约100,000的范围内),其被包含在广口瓶或类似物中,使消费者在使用该产品时能够看见霜膏的表面。在该实施方案中,所述组合物是霜膏组合物。
使用方法
申请人已经发现,本发明组合物可用于多种涉及增强哺乳动物皮肤的应用。本文公开并受权利要求书保护的组合物的使用方法包括但不限于:1)增加化妆品对皮肤亲和性的方法;2)保湿皮肤的方法;3)改善皮肤的自然外观的方法;4)向皮肤施用有色化妆品的方法;5)预防、延迟和/或治疗皱纹的方法;6)向皮肤提供紫外线防护的方法;7)预防、延迟和/或控制油性外观的方法;8)改善皮肤感觉和纹理的方法;9)提供均匀的皮肤色调的方法;10)预防、延迟和/或治疗蛛形血管和静脉曲张外观的方法;11)掩盖皮肤上毫毛外观的方法;和12)隐***的皮肤上瑕疵和/或缺陷(包括粉刺、老年斑、雀斑、痣、疤痕、黑眼圈、胎记、发炎后色素沉着过度等)的方法。本文所论述的每种方法均涉及将受权利要求书保护的组合物局部施用到皮肤上。
测试方法
表面的算术平均偏差测量
算术平均偏差(Sa)在环境条件下通过可商购获得的类似3-D地形测量的Primos-compact(GFMesstechnik GmbH,Berlin,Germany)测量。Sa的测量基于光学条纹投影技术,其投射平行条纹图案至将要测量的材料的表面上(S.Jaspers等人,Rapid in vivo measurement of thetopography of human skin by active image triahgulation using adigital micromirror device,Skin Research and Technology,5,195至207,1999)。组合物表面的粗糙度按平均粗糙度(Sa-值)计算。Sa是通常用于粗糙度的参数,并且其如下描述:
其中,M是评估的长度,N是评估的宽度,并且η(xi,yj)是高度曲线函数。评估的长度和宽度是沿粗糙度评估进行的总长度和宽度。高度曲线函数η(xi,yj)是在参考线以上或以下的振幅,其通过Z形曲线给出,通过这样的方式显示在上面和下面的曲线的面积是相等的。因此,Sa是面积的和(其存在于曲线和参考线之间)除以评估的长度。
粘度测量
通过可商购获得的粘度计如配备Helipath T-C棒型锭子的BROOKFIELD DV II+粘度计(BROOKFIELD ENGINEERING LABORATORIES,INC.)在25℃下以5rpm/min的测定产品的粘度。
摆动频率测量
Tanδ和G’通过使用AR-G2应力控制流变仪(TA InstrumentsJapan Inc.)或它的等同物的动态摆动测量而测量。将样本组合物置于40mm直径的铝平行板和Peltier板之间,使用Peltier***或其等同物将其控制在约25℃的温度。样本的厚度大约为1mm。在所述组合物的线性粘弹响应之内以外加的恒定应力(10dyne/cm2)以摆动频率模式(从0.06283rad/sec至251rad/sec)在所述组合物上进行动态频率扫描。在该测量中,将摆动剪切应力施加在所述组合物上,并且测量相应的剪切响应。该应力由具有位移的同相分力(储能模量,G’)和90°异相的分力(损耗模量,G”)所限定。结果被描述为从0.06283rad/sec至251rad/sec的各种角频率的G’和tanδ(G”/G’的比率)。
实施例
以下实施例进一步描述和例证了本发明保护范围内的实施方案。所给的这些实施例仅仅是说明性的,不可理解为是对本发明的限制,因为在不脱离本发明实质和范围的条件下可以具有许多变型。
组合物由以下组分通过常规方法制备。
依照粘度测量摆动频率测量来测量实施例和比较实施例的粘度。
1)Arlatone 2121(脱水山梨醇硬脂酸酯和蔗糖椰油酸酯):得自Uniqema
2)Nikkomulese LH(甘油、氢化卵磷脂、羟丙基甲基纤维素硬脂氧基醚、角鲨烷和甲基硬脂酰牛磺酸钠):得自Nikko Chemicals
3)Pemulen TR-2(丙烯酸酯/C10-30丙烯酸烷基酯交联聚合物):得自Noveon Inc.
4)Timiron MP-1001 Supersheen(云母和TiO2):得自EMD Chemicals Inc
5)Speron L-1500(二氧化硅):得自Presperse,Inc.
6)Tospearl 145A(聚甲基倍半硅氧烷):得自GE Toshiba Silicone Co.,Ltd.
7)二氧化钛GLW75CAP-MP 75%(TiO2、水和甘油):得自Kobo Products Inc.,
8)Aminocoat(甜菜碱):得自Asahi Kasei Chemicals Co.
9)Pellicer LC-30(二月桂酰胺基谷酰胺基赖氨酸钠和水):得自Asahi KaseiChemicals Co.
10)Sepiwhite Msh(十一碳烯酰苯基丙氨酸):得自Seppic
11)Myrj 59P(PEG-100硬脂酸酯):得自Uniqema
12)Tetraglyn 5-SV(聚甘油基-4五硬脂酸酯):得自Nikko Chemicals Co.
13)Rheodol 10SV(脱水山梨醇硬脂酸酯):得自Kao Co.
14)Arlamol E(PPG-15硬脂基醚):得自Uniqema
15)KSG-15(环戊硅氧烷和聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物):得自Shin-Etsu Chemical Co.,
16)KF96A-6CS(聚二甲基硅氧烷):得自Shin-Estu Chemical Co.
17)Sepigel 305(聚丙烯酰胺、C13-14异链烷烃和月桂基聚氧乙烯醚-7):得自Seppic
18)Dow Corning DC 1503 Fluid(聚二甲基硅氧烷和聚二甲基硅氧烷醇):得自DowCorning Corporation
将A相、B相、C相、D相和E相的成分加入各个合适的容器中,并且使用合适的搅拌器(例如锚式叶片、螺旋式叶片、IKA T25)混合每个相以获得均匀的相。当每个相均一化时,将D相缓慢加入到A相中,同时用适宜的搅拌器(例如,锚式叶片、螺旋式叶片,IKA T25)混合A相。当该批料均一化时,将B相、C相和E相缓慢加入到所获得的A相和D相的混合物中,同时混合该批料(例如,锚式叶片、螺旋式叶片,IKAT25)。持续搅拌直到该批料均匀。将产品倒入广口瓶中。
依照如测试方法中所存在的表面的算术平均偏差测量使用Primos-compact(得自GFMesstechnik GmbH,Berlin,Germany)测试所选择的实施例和比较实施例以测量Sa。将分别包含在30g广口瓶中的30g实施例1至4和比较实施例1至3的每个组合物置于环境条件下至少24小时,并且测量每个样本的Sa。在用手指将每个样本的表面变形后,立即测量每个样本的Sa。将样本置于环境条件下,并且在变形后4小时、8小时或24小时测量每个样本的Sa。
Sa | 实施例1 | 实施例2 | 实施例3 | 实施例4 | C.1 | C.2 | C.3 |
变形前 | 54.95 | 37.72 | 24.23 | 9.89 | 123.06 | 49.20 | 33.70 |
变形后0小时 | 313.57 | 220.82 | 135.68 | 180.03 | 202.15 | 200.68 | 39.40 |
变形后4小时 | - | - | - | 29.50 | - | - | - |
变形后8小时 | 103.25 | 43.82 | 22.70 | - | - | - | - |
变形后24小时 | 76.57 | 38.38 | 24.13 | 11.42 | 142.74 | 174.64 | 19.04 |
实施例3和比较实施例2的照片以图1A至D和2A至D提供。图1A至D是实施例3分别在变形前,变形后立即、以及变形后8小时和24小时拍的照片。图2A至D是比较实施例2在同样的时间点拍的照片。
依照如测试方法中所存在的摆动频率测量测试实施例和比较实施例以测定组合物的tanδ和G’。在25℃以10dyne/cm2的恒定摆动应力运行AR-G2。所测试实施例的所得的tanδ数据图提供在图3中,而G’数据提供在图4中。
应当理解,本发明实施例和实施方案的前述发明详述的提供仅仅用于举例说明之目的,并且对于本领域技术人员来说显而易见的是,在不背离本发明实质和范围的情况下可以做出多个其他改变和变型;并且权利要求书意欲包括在本发明范围内的所有这样的改变和变型。
在发明详述中引用的所有文件都在相关部分中以引用方式并入本文中。对于任何文件的引用不应当解释为承认其是有关本发明的现有技术。当本发明中术语的任何含义或定义与以引入方式并入的文件中术语的任何含义或定义矛盾时,应当服从在本发明中赋予该术语的含义或定义。
虽然已经举例说明和描述了本发明的具体实施方案,但是对于本领域的技术人员来说显而易见的是,在不背离本发明的实质和范围的情况下可以做出多个其它改变和变型。因此,权利要求书意欲包括在本发明范围内的所有这样的改变和变型。
Claims (16)
1.一种化妆品组合物,所述组合物包含:
a)约0.1%至约10%的疏水性结构化试剂;
b)约0.1%至约10%的亲水性表面活性剂;
c)约0.01%至约5%的非交联的水溶性聚合物;和
d)水,
其中所述组合物具有高于约15,000cps的粘度,并且在约0.1rad/sec至约1rad/sec的角频率范围内具有低于约15,000dyne/cm2的最高G’和高于约0.4的最高tanδ。
2.如权利要求1所述的组合物,其中所述组合物具有在约20,000cps至约100,000cps范围内的粘度。
3.如权利要求1所述的组合物,其中所述组合物在约0.1rad/sec至约1rad/sec的角频率范围内具有高于约0.5的最高tanδ。
4.如权利要求1所述的组合物,其中所述疏水性结构化试剂选自由下列组成的组:饱和的C16至C30脂肪醇、包含约1至约5摩尔环氧乙烷的饱和的C16至C30脂肪醇、饱和的C16至C30二醇、饱和的C16至C30单甘油醚、饱和的C16至C30羟基脂肪酸、饱和的C16至C30酸单己糖醇酯以及它们的混合物,所述疏水性结构化试剂具有至少约40℃的熔点。
5.如权利要求1所述的组合物,其中所述亲水性表面活性剂选自由下列组成的组:非离子表面活性剂、阴离子表面活性剂、阳离子表面活性剂、两性表面活性剂以及它们的混合物。
6.如权利要求1所述的组合物,其中所述非交联的水溶性聚合物是树胶型聚合物。
7.如权利要求1所述的组合物,其中所述非交联的水溶性聚合物是多糖聚合物。
8.如权利要求1所述的组合物,其中所述组合物是水包油型组合物。
9.如权利要求1所述的组合物,所述组合物还包含至少一种化合物,所述化合物选自由下列组成的组:护肤活性物质、皮肤调理剂、油溶性化合物、防晒剂以及它们的混合物。
10.如权利要求9所述的组合物,其中所述护肤活性物质选自由下列组成的组:维生素B3化合物、美白活性物质、肽、糖胺以及它们的混合物。
11.如权利要求9所述的组合物,其中所述护肤活性物质选自由下列组成的组:十一碳烯酰苯基丙氨酸和氯化十六烷基吡啶鎓。
12.一种美容产品,所述产品包含:
a)组合物,所述组合物包含:
i)约0.1%至约10%的疏水性结构化试剂;
ii)约0.1%至约10%的亲水性表面活性剂;
iii)约0.01%至约5%的非交联的水溶性聚合物;和
iv)水;以及
b)容器,所述容器容纳所述组合物,
其中所述组合物具有高于约15,000cps的粘度,并且在约0.1rad/sec至约1rad/sec的角频率范围内具有低于约15,000dyne/cm2的最高G’和高于约0.4的最高tanδ。
13.一种美容产品,所述产品包含:
a)组合物,所述组合物包含:
i)约0.1%至约10%的疏水性结构化试剂;
ii)约0.1%至约10%的表面活性剂;
iii)约0.01%至约5%的非交联的水溶性聚合物;和
iv)水;以及
b)容器,所述容器容纳所述组合物,
其中所述组合物具有高于15,000cps的粘度,并且当其表面被扭曲以具有高于约150的Sa时,在约24小时内恢复其表面平整度至具有低于约80的Sa。
14.如权利要求13所述的产品,其中所述产品当其表面被扭曲以具有高于约150的Sa时,在约12小时内恢复其表面平整度至具有低于约40的Sa。
15.如权利要求13所述的产品,其中所述容器是广口瓶。
16.一种制备如权利要求1所述的组合物的方法,所述方法包括:
a)通过混合疏水性结构化试剂和亲水性表面活性剂以及用于油相的任选成分来制备油相;
b)通过混合水溶性树胶型聚合物、水和用于所述油相的任选成分来制备含水相;和
c)将所述油相分散到所述含水相中。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88059807P | 2007-01-16 | 2007-01-16 | |
US60/880,598 | 2007-01-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101578086A true CN101578086A (zh) | 2009-11-11 |
Family
ID=39309999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA200880001821XA Pending CN101578086A (zh) | 2007-01-16 | 2008-01-15 | 化妆品组合物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20080169215A1 (zh) |
EP (1) | EP2101718A1 (zh) |
JP (1) | JP2010515720A (zh) |
KR (2) | KR20090089459A (zh) |
CN (1) | CN101578086A (zh) |
WO (1) | WO2008087591A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102791913A (zh) * | 2010-01-04 | 2012-11-21 | 特雷维拉股份有限公司 | 新的双组分纤维 |
CN104768523A (zh) * | 2012-10-29 | 2015-07-08 | 宝洁公司 | 10℃下具有0.30或更大损耗角正切值的个人护理组合物 |
US9498420B2 (en) | 2013-05-01 | 2016-11-22 | The Procter & Gamble Company | Cosmetic compositions and methods for inhibiting melanin synthesis |
CN106470665A (zh) * | 2014-04-23 | 2017-03-01 | 宝洁公司 | 具有减少刺激的化妆品组合物 |
US9757317B2 (en) | 2014-09-12 | 2017-09-12 | The Procter & Gamble Company | Cosmetic compositions and methods for inhibiting melanin synthesis |
CN108431091A (zh) * | 2016-02-19 | 2018-08-21 | 瓦克化学股份公司 | 硅酮橡胶颗粒分散的乳液的制造方法 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8729000B2 (en) * | 2007-12-12 | 2014-05-20 | Kimberly-Clark Worldwide, Inc. | Single use multi-phase care system |
WO2010059466A1 (en) * | 2008-11-24 | 2010-05-27 | The Procter & Gamble Company | Cosmetic compositions |
JP5627086B2 (ja) * | 2010-08-30 | 2014-11-19 | 花王株式会社 | 化粧料のぬるつきの評価方法 |
CN103327965B (zh) | 2011-01-25 | 2017-07-18 | 宝洁公司 | 脂质体和包含脂质体的个人护理组合物 |
CN104968237A (zh) * | 2013-02-07 | 2015-10-07 | 宝洁公司 | 施用器 |
US9511144B2 (en) | 2013-03-14 | 2016-12-06 | The Proctor & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
CN105163716B (zh) * | 2013-07-03 | 2019-02-12 | 株式会社利他药业 | 水溶性透明质酸凝胶及其制造方法 |
CA2932156A1 (en) * | 2013-12-24 | 2015-07-02 | The Procter & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
JP2016117690A (ja) * | 2014-12-22 | 2016-06-30 | ポーラ化成工業株式会社 | 乳化型皮膚外用剤 |
FR3037790B1 (fr) * | 2015-06-23 | 2019-06-07 | Laboratoires De Biologie Vegetale Yves Rocher | Composition cosmetique comprenant une vitamine, un lipoaminoacide et un polysaccharide |
US10549129B2 (en) | 2016-06-24 | 2020-02-04 | The Procter & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
JP7058943B2 (ja) * | 2017-03-30 | 2022-04-25 | 株式会社コーセー | 水中油型乳化組成物 |
WO2019120590A1 (en) * | 2017-12-22 | 2019-06-27 | Lvmh Recherche | Oil-in-water emulsified cosmetic |
CN112165929A (zh) * | 2018-06-06 | 2021-01-01 | 株式会社资生堂 | 使用部分交联或交联型二甲基聚硅氧烷的水包油型乳化化妆品 |
CN108969444B (zh) * | 2018-09-19 | 2021-02-02 | 青岛生康盛生物科技有限公司 | 一种去黑眼圈、抗皱紧肤修护眼霜及其制备方法 |
JP7179326B2 (ja) * | 2018-11-19 | 2022-11-29 | 株式会社サクラクレパス | 水性美爪料組成物 |
JP6921288B1 (ja) * | 2020-09-30 | 2021-08-18 | ポーラ化成工業株式会社 | 水中油型乳化組成物 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02121907A (ja) * | 1988-10-31 | 1990-05-09 | Mitsubishi Heavy Ind Ltd | 人用化粧料 |
US5939082A (en) * | 1995-11-06 | 1999-08-17 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
CA2251790C (en) * | 1996-04-23 | 2003-10-21 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin b3 compound |
WO1998034591A1 (en) * | 1997-02-11 | 1998-08-13 | The Procter & Gamble Company | Skin lightening compositions |
US5968528A (en) * | 1997-05-23 | 1999-10-19 | The Procter & Gamble Company | Skin care compositions |
DE19814608C1 (de) * | 1998-04-01 | 1999-09-23 | Henkel Kgaa | Verfahren zur Herstellung von kosmetischen Reinigungsmitteln mit erhöhter Viskosität |
BR9816071A (pt) * | 1998-11-13 | 2001-08-14 | Procter & Gamble | Emulsão de óleo-em-água contendo um composto de ácido ascórbico |
FR2787323B1 (fr) * | 1998-12-22 | 2003-02-14 | Seppic Sa | Utilisation de composes n-acyles d'aminoacides comme agent de texture |
KR100455470B1 (ko) * | 1999-05-17 | 2004-11-06 | 더 프록터 앤드 갬블 캄파니 | 피토스테롤 조성물의 국소 적용을 통한 포유류 케라틴조직 상태의 조절 방법 |
WO2001052795A2 (en) * | 2000-01-19 | 2001-07-26 | The Procter & Gamble Company | Skin care compositions |
DE10033975B4 (de) * | 2000-07-06 | 2004-08-12 | Coty B.V. | Gelierte feste kosmetische Zusammensetzung mit spezifischer Rheologie und deren Verwendung |
JP2002029933A (ja) * | 2000-07-19 | 2002-01-29 | Kao Corp | 毛髪化粧料 |
FR2835252B1 (fr) * | 2002-01-25 | 2005-08-05 | Seppic Sa | Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaicir la peau |
JP4708015B2 (ja) * | 2002-06-04 | 2011-06-22 | ザ プロクター アンド ギャンブル カンパニー | ゲル網状組織を含有するシャンプー |
US8349302B2 (en) * | 2002-06-04 | 2013-01-08 | The Procter & Gamble Company | Shampoo containing a gel network and a non-guar galactomannan polymer derivative |
US8361448B2 (en) * | 2002-06-04 | 2013-01-29 | The Procter & Gamble Company | Shampoo containing a gel network |
US20040175347A1 (en) * | 2003-03-04 | 2004-09-09 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using hexamidine compositions |
EP1481663A1 (en) * | 2003-05-27 | 2004-12-01 | The Procter & Gamble Company | Stable cosmetic compositions comprising a self-tanning agent |
WO2005000248A2 (en) * | 2003-06-25 | 2005-01-06 | Geron Corporation | Compositions and methods for skin conditioning |
EP1493430B1 (en) * | 2003-07-03 | 2009-11-11 | The Procter & Gamble Company | Self-tanning compositions comprising a water-soluble vitamin B3 compound and an alpha-hydroxycarbonyl self-tanning agent |
US7754775B2 (en) * | 2004-04-23 | 2010-07-13 | Mercier Michel F | Multi-lamellar liquid crystal emulsion system |
EP1833456A1 (en) * | 2004-07-23 | 2007-09-19 | The Procter and Gamble Company | Skin care composition containing a flavonoid and vitamin b3 |
-
2008
- 2008-01-15 CN CNA200880001821XA patent/CN101578086A/zh active Pending
- 2008-01-15 WO PCT/IB2008/050135 patent/WO2008087591A1/en active Application Filing
- 2008-01-15 EP EP08702433A patent/EP2101718A1/en not_active Withdrawn
- 2008-01-15 KR KR1020097014328A patent/KR20090089459A/ko not_active Application Discontinuation
- 2008-01-15 KR KR1020127020018A patent/KR20120113765A/ko not_active Application Discontinuation
- 2008-01-15 JP JP2009545285A patent/JP2010515720A/ja active Pending
- 2008-01-16 US US12/009,051 patent/US20080169215A1/en not_active Abandoned
-
2011
- 2011-01-18 US US13/008,734 patent/US20110110874A1/en not_active Abandoned
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102791913A (zh) * | 2010-01-04 | 2012-11-21 | 特雷维拉股份有限公司 | 新的双组分纤维 |
CN103497406A (zh) * | 2010-01-04 | 2014-01-08 | 特雷维拉股份有限公司 | 新的双组分纤维 |
CN102791913B (zh) * | 2010-01-04 | 2014-09-17 | 特雷维拉股份有限公司 | 新的双组分纤维 |
CN103497406B (zh) * | 2010-01-04 | 2016-12-28 | 陶氏化学公司 | 双组分纤维 |
CN104768523A (zh) * | 2012-10-29 | 2015-07-08 | 宝洁公司 | 10℃下具有0.30或更大损耗角正切值的个人护理组合物 |
US9498420B2 (en) | 2013-05-01 | 2016-11-22 | The Procter & Gamble Company | Cosmetic compositions and methods for inhibiting melanin synthesis |
CN104768525B (zh) * | 2013-05-01 | 2017-09-26 | 宝洁公司 | 化妆品组合物和用于抑制黑素合成的方法 |
CN106470665A (zh) * | 2014-04-23 | 2017-03-01 | 宝洁公司 | 具有减少刺激的化妆品组合物 |
CN106470665B (zh) * | 2014-04-23 | 2019-12-24 | 宝洁公司 | 具有减少刺激的化妆品组合物 |
US9757317B2 (en) | 2014-09-12 | 2017-09-12 | The Procter & Gamble Company | Cosmetic compositions and methods for inhibiting melanin synthesis |
CN108431091A (zh) * | 2016-02-19 | 2018-08-21 | 瓦克化学股份公司 | 硅酮橡胶颗粒分散的乳液的制造方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2008087591A1 (en) | 2008-07-24 |
KR20120113765A (ko) | 2012-10-15 |
US20080169215A1 (en) | 2008-07-17 |
JP2010515720A (ja) | 2010-05-13 |
EP2101718A1 (en) | 2009-09-23 |
KR20090089459A (ko) | 2009-08-21 |
US20110110874A1 (en) | 2011-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101578086A (zh) | 化妆品组合物 | |
KR101249227B1 (ko) | 피부 케어 조성물 | |
US20210121379A1 (en) | Composition comprising at least two fatty acid esters of (poly)glycerol, and use thereof in cosmetics | |
CN101677911B (zh) | 多制剂化妆品组合物 | |
US9446265B2 (en) | Cosmetic composition | |
CN103221022A (zh) | 基于n-酰基氨基酸化合物和己基癸醇的化妆品组合物 | |
JP2021533079A (ja) | 肌修復用スキンケア組成物及びその調製方法 | |
KR100450483B1 (ko) | 투명한 마이크로 에멀젼 | |
JP6313961B2 (ja) | 水中油型乳化組成物 | |
KR20100088580A (ko) | 눈 자극이 감소된 개인 케어 썬스크린 조성물 | |
JP2015514777A (ja) | 化粧品組成物 | |
CN102946850A (zh) | 皮肤改善皮肤化妆品 | |
CN106860088A (zh) | 一种美白祛疤护肤品及其制备方法 | |
KR20200075424A (ko) | 미백능과 항노화능이 뛰어난 화장품 조성물 및 이의 제조방법 | |
EP3075375A1 (en) | External preparation for skin | |
CN117881383A (zh) | 包含多羟基酸的透明组合物 | |
KR100809897B1 (ko) | 피부 미백제를 포함하는 피부 케어 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1134242 Country of ref document: HK |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20091111 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1134242 Country of ref document: HK |